Pardoprunox hydrochloride is primarily investigated for its potential therapeutic applications in treating neurological and psychiatric disorders. It acts as a partial agonist of dopamine D2 and serotonin 5-HT1A receptors, making it a candidate for managing conditions like Parkinson's disease and schizophrenia. In Parkinson's, it may help alleviate motor symptoms by modulating dopamine activity while reducing side effects such as dyskinesias. For schizophrenia, its dual receptor activity could improve both positive and negative symptoms, offering a more balanced treatment approach. Additionally, its anxiolytic properties are being explored for potential use in anxiety disorders. Research continues to evaluate its efficacy, safety, and optimal dosing in clinical settings.